HC Wainwright Upgrades Sensei Biotherapeutics (NASDAQ:SNSE) to Buy

Sensei Biotherapeutics (NASDAQ:SNSE) was upgraded by equities researchers at HC Wainwright to a “buy” rating in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage currently has a $5.00 target price on the stock.

A number of other research firms have also issued reports on SNSE. Oppenheimer boosted their price target on shares of Sensei Biotherapeutics from $3.50 to $4.00 and gave the company an “outperform” rating in a report on Friday, March 28th. Stephens upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, May 1st.

Sensei Biotherapeutics Price Performance

NASDAQ SNSE opened at $0.34 on Monday. The company’s 50 day simple moving average is $0.36 and its 200 day simple moving average is $0.44. Sensei Biotherapeutics has a 12 month low of $0.25 and a 12 month high of $0.87. The company has a market capitalization of $8.52 million, a P/E ratio of -0.28 and a beta of 0.19.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). On average, analysts anticipate that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd boosted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,903 shares of the company’s stock after purchasing an additional 48,977 shares during the period. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent reporting period. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.